Affiliation:
1. Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences (PUMS), Poznan, Poland
2. Student Nephrology Research Group, Department of Nephrology, Transplantology and Internal Diseases, PUMS, Poznan, Poland
3. Department of Biophysics, PUMS, Poznan, Poland
Abstract
Background: IFNL4 polymorphisms are associated with circulating IFN-λ3,
and higher plasma IFN-λ3 are associated with higher production of antibodies to HBV
surface antigen (anti-HBs). The IFNL4 rs8099917 T allele and anti-HBs development in
response to HBV vaccine are associated with better survival in hemodialysis (HD)
patients.
Objective:
To show whether plasma IFN-λ3 is also a predictor of survival in HD
patients.
Methods:
Plasma IFN-λ3 was measured in 135 HD patients who were followed-up for
2.6 years. Survival probability was tested using the Kaplan-Meier method and the Cox
proportional hazard model.
Results:
Plasma IFN-λ3 (ng/L) was 116.8 (20.4–227.5) in survivors on HD (n=89,
65.9%), 75.1 (36.0-228.8) in deceased patients (n=37, 27.4%), and 109.0 (40.0–232.7)
in subjects submitted to kidney transplantation (n=9, 6.7%). IFN-λ3 was lower in
deceased patients than that in all remaining patients (P=0.039) and patients who
continued HD without transplantation (P=0.028). IFN-λ3 and anti-HBs titers were
correlated (r=0.587, P<0.000001). Patients showing IFN-λ3 >126.1 ng/L (3rd tertile)
presented better survival compared with patients with IFN-λ3 in the 1st (<73.8 ng/L,
P=0.005) and 2nd (≥73.8 - <126.1 ng/L, P=0.013) tertiles. Each decrease in IFN-λ3 per
10 ng/L was associated with a hazard ratio equal to 1.076 (95%CI 1.015–1.140,
P=0.013). In multivariate analysis, the independent predictors of survival were age
(P=0.008), dialysis modality (P=0.038), circulating IFN-λ3 (P=0.044), and diabetic
nephropathy (P=0.047), but not gender, dialysis duration prior to the study, mean arterial
pressure, BMI, CRP, albumin, 25(OH)D, or anti-HBs.
Conclusion:
Circulating IFN-λ3 is a promising predictor of HD patient survival.
Publisher
Bentham Science Publishers Ltd.
Subject
Molecular Biology,Molecular Medicine,General Medicine,Biochemistry
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献